NSE filing, NSE: JBCHEPHARM. Summary written from the filing by ALFA Finder's alert engine.
More from Jb Chemicals & Pharmaceuticals Limited
All →Jb Chemicals & Pharmaceuticals Merger & Restructuring
JB Chemicals & Pharmaceuticals' amalgamation with Torrent Pharmaceuticals received NCLT sanction. The scheme will become effective upon filing with the Registrar of Companies.
Jb Chemicals & Pharmaceuticals Management Change
Pradeep Kumar Singh and Suresh Bhise retired from the company. These changes in senior management are effective from June 30, 2026.
Jb Chemicals & Pharmaceuticals Price Movement Clarification
JB Chemicals clarified its audited financial results to the exchange. The board-approved results were signed by a director as authorized.
Jb Chemicals & Pharmaceuticals Management Change
Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management effective June 12, 2026. Investors should note the departure of a key supply chain executive.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details company ESG performance, sustainability targets, and governance frameworks.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals filed its FY26 Business Responsibility and Sustainability Report. The filing highlights its ₹3889.89 Crore turnover and ESG progress for investor review.
- Value
- ₹3,890 Cr
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr